Aevi Genomic Medicine (NASDAQ:GNMX) Shares Up 11.1%

Share on StockTwits

Shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) shot up 11.1% during mid-day trading on Monday . The company traded as high as $0.20 and last traded at $0.20, 768,965 shares traded hands during trading. A decline of 64% from the average session volume of 2,151,747 shares. The stock had previously closed at $0.18.

Separately, ValuEngine raised shares of Aevi Genomic Medicine from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The company has a market cap of $12.63 million, a P/E ratio of -0.39 and a beta of 0.73. The stock’s 50-day moving average price is $0.18 and its 200-day moving average price is $0.20.

An institutional investor recently raised its position in Aevi Genomic Medicine stock. Vanguard Group Inc. lifted its stake in shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 82.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,252,050 shares of the biotechnology company’s stock after purchasing an additional 566,497 shares during the quarter. Vanguard Group Inc. owned about 1.93% of Aevi Genomic Medicine worth $201,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.99% of the company’s stock.

Aevi Genomic Medicine Company Profile (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Further Reading: What are the benefits of momentum investing?

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.